Clinical Trial Update: A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update announcing a Phase 1/2 study to evaluate the safety, tolerability, and efficacy of AB-1009 gene therapy for adult participants with late…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Late-onset Pompe Disease
• Pompe Disease

Drugs mentioned

• AB-1009 Gene Therapy (GAA Gene)

Snippet

Sponsor: AskBio Inc | Conditions: Pompe Disease (Late-onset), Pompe Disease Late-Onset | Phase 1, Phase 2 | Status: RECRUITING